Novo Nordisk’s Torrid Week Erases Last of Wegovy-Fueled Gains

Core Viewpoint - The stock performance of Novo Nordisk has significantly declined, erasing gains from the approval of its Wegovy obesity drug due to disappointing results from its next-generation obesity treatment, CagriSema [1][2]. Group 1: Stock Performance - Novo Nordisk's shares have dropped 21%, marking the steepest weekly decline since August, following a sales forecast that disappointed investors [1]. - The stock has lost nearly all of its fivefold gains achieved over the past five years, driven by optimism in the obesity-drug market [2]. Group 2: Product Performance - The recent launch of Wegovy pills has been highly successful, with over 240,000 Americans already using the medication [3]. - CagriSema, the next-generation obesity shot, achieved a weight loss of 20.2%, which is close to the 23.6% weight loss from Eli Lilly's tirzepatide, but has raised concerns about Novo's competitive edge [5]. Group 3: Analyst Reactions - Following the disappointing data for CagriSema, five analysts downgraded Novo's stock, indicating a significant impact on the investment case for the drug [4]. - Analysts from Deutsche Bank and JPMorgan have expressed concerns that the latest developments may limit the commercial potential of CagriSema [4]. Group 4: Future Outlook - Analysts suggest that Novo's ability to sustain its obesity franchise beyond the 2032 patent expiration may be questioned, especially with competitors developing more effective treatments [6].